Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Early Phase 1
4(50.0%)
Phase 1
4(50.0%)
8Total
Early Phase 1(4)
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07260812Phase 1Recruiting

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Role: lead

NCT07275853Phase 1Not Yet Recruiting

Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

Role: lead

NCT07246707Phase 1Recruiting

KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Role: collaborator

NCT07196579Phase 1Not Yet Recruiting

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

Role: lead

NCT05811975Early Phase 1Recruiting

KSX01-TCRT Injection Project in Solid Tumors

Role: lead

NCT05539833Early Phase 1Recruiting

KSH01-TCRT Solid Tumors

Role: lead

NCT05580796Early Phase 1Recruiting

KSH01-R02-101 Solid Tumors

Role: lead

NCT05447234Early Phase 1Not Yet Recruiting

TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy

Role: collaborator

All 8 trials loaded